3D-QSAR/CoMFA-based structure-affinity/selectivity relationships of aminoalkylindoles in the cannabinoid CB1 and CB2 receptors

Molecules

Volumn 19, Issue 3, 2014, Pages 2842-2861

  Mella Raipan, Jaime ^a   Hernandez Pino, Santiago ^a   Morales Verdejo, Cesar ^b   Pessoa Mahana, David ^c  

^a UNIVERSIDAD DE VALPARAÍSO   (Chile)

^b UNIVERSIDAD BERNARDO O'HIGGINS   (Chile)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

3D QSAR; Aminoalkylindole; Cannabinoid; CB1 CB2; Comparative Molecular Field Analysis (CoMFA); Molecular modelling; Simulated annealing; Structure activity relationships

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; LIGAND;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; METABOLISM; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STEREOISOMERISM;

LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; STEREOISOMERISM;

EID: 84896976829     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules19032842     Document Type: Article

References (40)

1. Howlett, A.C. The cannabinoid receptors. Prostag. Other Lipid Mediat. 2002, 68-69, 619-631.
2. Gaoni, Y.; Mechoulam, R. Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 1964, 86, 1646-1647.
3. Adams, I.B.; Martin, B.R. Cannabis: Pharmacology and toxicology in animals and humans. Addiction 1996, 91, 1585-1614.
4. Lambert, D.M. Medical use of cannabis through history. J. Pharm. Belg. 2001, 56, 111-118.
5. Pacher, P.; Mechoulam, R. Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog. Lipid Res. 2011, 50, 193-211.
6. Sheng, W.S.; Hu, S.; Min, X.; Cabral, G.A.; Lokensgard, J.R.; Peterson, P.K. Synthetic cannabinoid win55,212-2 inhibits generation of inflammatory mediators by il-1beta-stimulated human astrocytes. Glia 2005, 49, 211-219.
7. Cinar, R.; Szucs, M. Cb1 receptor-independent actions of sr141716 on g-protein signaling: Coapplication with the mu-opioid agonist tyr-d-ala-gly-(nme)phe-gly-ol unmasks novel, pertussis toxin-insensitive opioid signaling in mu-opioid receptor-chinese hamster ovary cells. J. Pharmacol. Exp. Ther. 2009, 330, 567-574.
8. Di Marzo, V.; Matias, I. Endocannabinoid control of food intake and energy balance. Nat. Neurosci. 2005, 8, 585-589.
9. Herkenham, M.; Lynn, A.B.; de Costa, B.R.; Richfield, E.K. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. 1991, 547, 267-274.
10. Herkenham, M.; Lynn, A.B.; Johnson, M.R.; Melvin, L.S.; de Costa, B.R.; Rice, K.C. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J. Neurosci. 1991, 11, 563-583.
11. Herkenham, M.; Lynn, A.B.; Little, M.D.; Johnson, M.R.; Melvin, L.S.; de Costa, B.R.; Rice, K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA 1990, 87, 1932-1936.
12. Mackie, K. Cannabinoid receptors: Where they are and what they do. J. Neuroendocrinol. 2008, 20 (Suppl. 1), 10-14.
13. Di Marzo, V. Cb(1) receptor antagonism: Biological basis for metabolic effects. Drug Discov. Today 2008, 13, 1026-1041.
14. Bouaboula, M.; Rinaldi, M.; Carayon, P.; Carillon, C.; Delpech, B.; Shire, D.; le Fur, G.; Casellas, P. Cannabinoid-receptor expression in human leukocytes. Eur. J. Biochem. 1993, 214, 173-180.
15. Galiegue, S.; Mary, S.; Marchand, J.; Dussossoy, D.; Carriere, D.; Carayon, P.; Bouaboula, M.; Shire, D.; le Fur, G.; Casellas, P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 1995, 232, 54-61.
16. Carrier, E.J.; Kearn, C.S.; Barkmeier, A.J.; Breese, N.M.; Yang, W.; Nithipatikom, K.; Pfister, S.L.; Campbell, W.B.; Hillard, C.J. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a cb2 receptor-dependent mechanism. Mol. Pharmacol. 2004, 65, 999-1007.
17. Di Marzo, V.; Bifulco, M.; de Petrocellis, L. The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov. 2004, 3, 771-784.
18. Nunez, E.; Benito, C.; Pazos, M.R.; Barbachano, A.; Fajardo, O.; Gonzalez, S.; Tolon, R.M.; Romero, J. Cannabinoid cb2 receptors are expressed by perivascular microglial cells in the human brain: An immunohistochemical study. Synapse 2004, 53, 208-213.
19. Walter, L.; Franklin, A.; Witting, A.; Wade, C.; Xie, Y.; Kunos, G.; Mackie, K.; Stella, N. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci. 2003, 23, 1398-1405.
20. Berdyshev, E.V. Cannabinoid receptors and the regulation of immune response. Chem. Phys. Lipids 2000, 108, 169-190.
21. Molina-Holgado, E.; Guaza, C.; Borrell, J.; Molina-Holgado, F. Effects of cannabinoids on the immune system and central nervous system: Therapeutic implications. BioDrugs 1999, 12, 317-326.
22. Mackie, K. Cannabinoid receptors as therapeutic targets. Annu. Rev. Pharmacol. Toxicol. 2006, 46, 101-122.
23. Frost, J.M.; Dart, M.J.; Tietje, K.R.; Garrison, T.R.; Grayson, G.K.; Daza, A.V.; El-Kouhen, O.F.; Miller, L.N.; Li, L.; Yao, B.B.; et al. Indol-3-yl-tetramethylcyclopropyl ketones: Effects of indole ring substitution on cb2 cannabinoid receptor activity. J. Med. Chem. 2008, 51, 1904-1912.
24. Frost, J.M.; Dart, M.J.; Tietje, K.R.; Garrison, T.R.; Grayson, G.K.; Daza, A.V.; El-Kouhen, O.F.; Yao, B.B.; Hsieh, G.C.; Pai, M.; et al. Indol-3-ylcycloalkyl ketones: Effects of n1 substituted indole side chain variations on cb(2) cannabinoid receptor activity. J. Med. Chem. 2010, 53, 295-315.
25. Pasquini, S.; Mugnaini, C.; Ligresti, A.; Tafi, A.; Brogi, S.; Falciani, C.; Pedani, V.; Pesco, N.; Guida, F.; Luongo, L.; et al. Design, synthesis, and pharmacological characterization of indol-3- ylacetamides, indol-3- yloxoacetamides, and indol-3-ylcarboxamides: Potent and selective cb2 cannabinoid receptor inverse agonists. J. Med. Chem. 2012, 55, 5391-5402.
26. Cramer, R.D.; Patterson, D.E.; Bunce, J.D. Comparative molecular field analysis (comfa). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
27. Chen, J.Z.; Han, X.W.; Liu, Q.; Makriyannis, A.; Wang, J.; Xie, X.Q. 3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach. J. Med. Chem. 2006, 49, 625-636.
28. Cichero, E.; Cesarini, S.; Mosti, L.; Fossa, P. CoMFA and CoMSIA analyses on 1,2,3,4- tetrahydropyrrolo[3,4-b]indole and benzimidazole derivatives as selective CB2 receptor agonists. J. Mol. Model. 2010, 16, 1481-1498.
29. Durdagi, S.; Kapou, A.; Kourouli, T.; Andreou, T.; Nikas, S.P.; Nahmias, V.R.; Papahatjis, D.P.; Papadopoulos, M.G.; Mavromoustakos, T. The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1' position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2. J. Med. Chem. 2007, 50, 2875-2885.
30. Durdagi, S.; Papadopoulos, M.G.; Mavromoustakos, T. An effort to discover the preferred conformation of the potent amg3 cannabinoid analog when reaching the active sites of the cannabinoid receptors. Eur. J. Med. Chem. 2012, 47, 44-51.
31. Durdagi, S.; Papadopoulos, M.G.; Zoumpoulakis, P.G.; Koukoulitsa, C.; Mavromoustakos, T. A computational study on cannabinoid receptors and potent bioactive cannabinoid ligands: Homology modeling, docking, de novo drug design and molecular dynamics analysis. Mol. Diver. 2010, 14, 257-276.
32. Alvarez-Figueroa, M.J.; Pessoa-Mahana, C.D.; Palavecino-Gonzalez, M.E.; Mella-Raipan, J.; Espinosa-Bustos, C.; Lagos-Munoz, M.E. Evaluation of the membrane permeability (pampa and skin) of benzimidazoles with potential cannabinoid activity and their relation with the biopharmaceutics classification system (bcs). AAPS PharmSciTech 2011, 12, 573-578.
33. Araya, K.A.; David Pessoa Mahana, C.; Gonzalez, L.G. Role of cannabinoid CB1 receptors and Gi/o protein activation in the modulation of synaptosomal Na+,K+-ATPase activity by WIN55,212-2 and delta(9)-THC. Eur. J. Pharm. 2007, 572, 32-39.
34. Mella-Raipan, J.A.; Lagos, C.F.; Recabarren-Gajardo, G.; Espinosa-Bustos, C.; Romero-Parra, J.; Pessoa-Mahana, H.; Iturriaga-Vasquez, P.; Pessoa-Mahana, C.D. Design, synthesis, binding and docking-based 3d-qsar studies of 2-pyridylbenzimidazoles-a new family of high affinity cb1 cannabinoid ligands. Molecules 2013, 18, 3972-4001.
35. Golbraikh, A.; Tropsha, A. Beware of q2! J. Mol. Graph. Model. 2002, 20, 269-276.
36. Vinter, J.G.; Davis, A.; Saunders, M.R. Strategic approaches to drug design. I. An integrated software framework for molecular modelling. J. Comput.-Aided Mol. Des. 1987, 1, 31-51.
37. Gasteiger, J.; Marsilili, M. Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges. Tetrahedron 1980, 36, 3219-3228.
38. Clark, M.; Cramer, R.; Opdenbosch, N. Validation of the general purpose tripos 5.2 force field. J. Comp. Chem. 1989, 10, 982-1012.
39. Oprea, T.I.; Waller, C.L.; Marshall, G.R. Three-dimensional quantitative structure-activity relationship of human immunodeficiency virus (i) protease inhibitors. 2. Predictive power using limited exploration of alternate binding modes. J. Med. Chem. 1994, 37, 2206-2215.
40. Waller, C.L.; Oprea, T.I.; Giolitti, A.; Marshall, G.R. Three-dimensional qsar of human immunodeficiency virus (i) protease inhibitors. 1. A comfa study employing experimentallydetermined alignment rules. J. Med. Chem. 1993, 36, 4152-4160.